Allspring Global Investments’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$345K Buy
20,007
+767
+4% +$10.7K ﹤0.01% 1546
2026
Q1
$255K Buy
19,240
+1,990
+12% +$25.3K ﹤0.01% 1559
2025
Q4
$159K Buy
17,250
+1,333
+8% +$18.4K ﹤0.01% 1596
2025
Q3
$299K Sell
15,917
-21
-0.1% -$259 ﹤0.01% 1485
2025
Q2
$157K Sell
15,938
-860
-5% -$7.06K ﹤0.01% 1564
2025
Q1
$112K Buy
16,798
+3,935
+31% +$39.7K ﹤0.01% 1690
2024
Q4
$157K Buy
12,863
+1,582
+14% +$24.7K ﹤0.01% 1692
2024
Q3
$232K Buy
11,281
+394
+4% +$9.08K ﹤0.01% 1650
2024
Q2
$244K Buy
10,887
+1,993
+22% +$47.5K ﹤0.01% 1670
2024
Q1
$245K Buy
8,894
+750
+9% +$20.8K ﹤0.01% 1663
2023
Q4
$248K Buy
8,144
+582
+8% +$16.7K ﹤0.01% 1651
2023
Q3
$239K Sell
7,562
-107
-1% -$4.15K ﹤0.01% 1716
2023
Q2
$313K Buy
7,669
+3,393
+79% +$138K ﹤0.01% 1678
2023
Q1
$159K Sell
4,276
-816
-16% -$32K ﹤0.01% 1885
2022
Q4
$178K Sell
5,092
-65
-1% -$3.09K ﹤0.01% 1865
2022
Q3
$288K Sell
5,157
-293
-5% -$18.2K ﹤0.01% 1710
2022
Q2
$282K Sell
5,450
-25,046
-82% -$1.27M ﹤0.01% 1723
2022
Q1
$2.22M Sell
30,496
-1,520
-5% -$129K ﹤0.01% 1452
2021
Q4
$3.79M Buy
+32,016
New +$4.01M ﹤0.01% 1275

Other funds holding NTLA

Allspring Global Investments's NTLA Position: Q2 2026 in Review

Allspring Global Investments increased its Intellia Therapeutics (NTLA) stake by 4% in Q2 2026, buying an estimated $10.7K and bringing the position to 20,007 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #1546.

Allspring Global Investments first reported a position in NTLA in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.79M in Q4 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Allspring Global Investments held 20,007 shares of Intellia Therapeutics worth $345K as of Q2 2026.
  • Allspring Global Investments bought 767 Intellia Therapeutics shares in Q2 2026, an estimated $10.7K.
  • Intellia Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1546 holding.
  • Allspring Global Investments first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Allspring Global Investments's Intellia Therapeutics position peaked at $3.79M in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.